Although IFN-α is widely used in clinical therapy for hepatitis B and hepatitis C, only 30%-40% CHB patients can realize HBeAg seroconversion and 50%-60% patients with genotype 1 cannot realize the sustained virological response (SVR). Here, IFNA1 is linked to hepatitis C virus infection.